Omeros (OMER) Shares Outstanding (2010 - 2026)
Omeros (OMER) posted Shares Outstanding (Entity) of $72.0 million for Q1 2026, little changed sequentially from $71.7 million in Q4 2025, and up 24.0% YoY from $58.1 million in Q1 2025.
Omeros (OMER) Shares Outstanding (2010 - 2026) Analysis & Trends
Omeros has reported Shares Outstanding (Entity) for 17 years, with the latest figure at $72.0 million in Q1 2026.
- Quarterly Shares Outstanding (Entity) rose 24.0% year-over-year to $72.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $72.0 million (up 24.0% YoY) and the FY2025 annual result came in at $71.7 million, up 23.48% from the prior year.
- Shares Outstanding (Entity) steadied at $72.0 million in Q1 2026 per OMER's latest filing, from $71.7 million in the prior quarter.
- Over five years, Shares Outstanding (Entity) peaked at $72.0 million in Q1 2026 and troughed at $57.9 million in Q1 2024.
- A 5-year average of $62.6 million and a median of $62.7 million in 2022 frame the typical range for Shares Outstanding (Entity).
- The sharpest annual moves came in 2024 and 2026: Shares Outstanding (Entity) slipped 7.82% in 2024, then advanced 24.0% in 2026.
- Over 5 years, Shares Outstanding (Entity) stood at $62.8 million in 2022, then fell by 2.71% to $61.1 million in 2023, then declined by 5.05% to $58.0 million in 2024, then increased by 23.48% to $71.7 million in 2025, then grew by 0.46% to $72.0 million in 2026.
- According to Business Quant data, Shares Outstanding (Entity) over the past three periods registered $72.0 million, $71.7 million, and $70.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 62.19 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 210.89 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.45 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 25.05 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 445.06 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 133.61 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 217.35 Mn |
| 10 | Omeros | 1.24 Bn | 1.24 Bn | 27.73 Mn | 72.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 71.92 Mn |
| Mar 31, 2026 | 71.92 Mn |
| Dec 31, 2025 | 63.51 Mn |
| Sep 30, 2025 | 66.26 Mn |
| Jun 30, 2025 | 58.59 Mn |
| Mar 31, 2025 | 58.06 Mn |
| Dec 31, 2024 | 58.17 Mn |
| Sep 30, 2024 | 57.95 Mn |
| Jun 30, 2024 | 57.94 Mn |
| Mar 31, 2024 | 58.80 Mn |
| Dec 31, 2023 | 62.74 Mn |
| Sep 30, 2023 | 62.86 Mn |
| Jun 30, 2023 | 62.84 Mn |
| Mar 31, 2023 | 62.83 Mn |
| Dec 31, 2022 | 62.74 Mn |
| Sep 30, 2022 | 62.73 Mn |
| Jun 30, 2022 | 62.73 Mn |
| Mar 31, 2022 | 62.72 Mn |
| Dec 31, 2021 | 62.34 Mn |
| Sep 30, 2021 | 62.51 Mn |